Clinical Trials
12 trialsNCT03586661 2026-03-11
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03884998 2025-12-30
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04895579 2025-11-18
LCD
University of Kentucky
Phase 1 Completed
NCT04462471 2025-09-08
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT04431635 2024-09-27
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04156828 2023-06-29
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
University of Washington
Phase 1 Terminated
NCT03128619 2022-09-26
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT05010096 2022-05-27
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03886649 2022-04-01
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Swiss Cancer Institute
Phase 1 Terminated
NCT04233697 2020-08-13
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Columbia University
Phase 1 Withdrawn